Chinese Conba Pharma’s Stocks Rally on Finishing First Hemp Cultivation

Chinese Conba Pharma’s Stocks Rally on Finishing First Hemp Cultivation

The share price of Conba Pharmaceutical’s soared today after the Chinese firm announced it has planted its first crop of industrial hemp. Conba Pharma’s [SHA:600572] share price rose by the daily limit of 10 percent to CNY6.60...

Read more
Gilead Strikes $2.48 Billion Deal with Nurix to Focus on Protein Degradation

Gilead Strikes $2.48 Billion Deal with Nurix to Focus on Protein Degradation

Gilead Sciences and Nurix, based in Forest City, Calif. and San Francisco, respectively, signed a global strategic collaboration deal that could hit $2.48 billion. The focus will be on discovering drugs that use the body’s natural protein control...

Read more
Cellular Bio Starts Phase I China Trial of CD20 CAR-T

Cellular Bio Starts Phase I China Trial of CD20 CAR-T

Cellular Biomedicine, a New York-Shanghai company, has started a China Phase I trial of its CD20 CAR-T candidate in patients who relapsed after CD19 treatment. The patients have either relapsed diffuse large B-cell lymphoma or small B-cell...

Read more
CARsgen Given Green Light for US Trials of BCMA CAR-T Candidate

CARsgen Given Green Light for US Trials of BCMA CAR-T Candidate

CARsgen Therapeutics, a Shanghai CAR-T company, was approved to start US trials of its fully human BCMA (B-Cell Maturation Antigen)-CAR-T therapy for patients with relapsed/refractory multiple myeloma. Four months ago, China’s NMPA approved...

Read more
Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production

Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production

Intrexon Corporation (Intrexon) (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve quality of life and health of the planet, and Surterra Wellness (Surterra), one of the fastest growing health and wellness...

Read more
BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

BeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks...

Read more
CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment

CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment

CASI Pharma, a US-China company, obtained global rights to an autologous anti-CD19 T-cell therapy developed by Juventas Cell Therapy of Tianjin City, China. Juventas has filed China INDs to test CNCT19 as a treatment for two leukemia and lymphoma...

Read more
Chi-Med’s Surufatinib Meets Survival Endpoint — Trial Stopped Early

Chi-Med’s Surufatinib Meets Survival Endpoint — Trial Stopped Early

Hutchison China MediTech (Chi-Med) will stop its Phase III trial of surufatinib early following positive interim data showing the candidate met its primary endpoint of progression-free survival. The China trial was testing surufatinib in patients...

Read more
Innovent’s BCMA CAR-T Produces 100% Response Rate in Myeloma Patients

Innovent’s BCMA CAR-T Produces 100% Response Rate in Myeloma Patients

Suzhou Innovent Biologics reported that its fully-human BCMA CAR-T candidate produced a 100% objective response rate in patients with relapsed/refractory multiple myeloma (RRMM). CT103A was co-developed by Innovent and Nanjing IASO...

Read more
Neptune Receives Health Canada’s Amendments to Expand Capacity to 200,000 kg and for Cannabis Oil Capsule Production

Neptune Receives Health Canada’s Amendments to Expand Capacity to 200,000 kg and for Cannabis Oil Capsule Production

Neptune Wellness Solutions Inc. (“Neptune” or the “Company”) (NASDAQ:NEPT) (TSX:NEPT) is pleased to announce that its wholly owned subsidiary, 9354-7537 Québec Inc., has received a notification letter from Health Canada...

Read more
Pfizer to Acquire Array BioPharma

Pfizer to Acquire Array BioPharma

Proposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term Opportunity to strengthen category leadership in Oncology with the addition of...

Read more
Jiangsu Hengrui In-Licenses Treatment for Yeast Infection from Mycovia

Jiangsu Hengrui In-Licenses Treatment for Yeast Infection from Mycovia

Jiangsu Hengrui Medicine in-licensed greater China rights to a treatment for chronic yeast infections from Mycovia Pharma of Durham, North Carolina. Mycovia is currently conducting a Phase III trial of VT-1161 (otesaconazole) in women with...

Read more
Do NOT follow this link or you will be banned from the site!